Unfortunately for investors, it missed on both the top and bottom lines. Apellis unveiled those results before market hours on Tuesday, disclosing that its revenue for the quarter was just under ...

Overall, Apellis reported total third-quarter revenues of $196.8 million, up 78% year over year. Beyond Syfovre, the company’s paroxysmal nocturnal hemoglobinuria drug Empaveli grew sales 0.4% ...

Apellis stock toppled Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations. Please watch the video at Investors.com - How To Buy Stocks ...

RBC Capital analyst Lisa Walter initiated coverage of Apellis (APLS) with a Sector Perform rating and $25 price target Complement inhibitors Syfovre and Izervay were approved for geographic ...

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2024 financial results and business highlights. “The third ...

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Laurie McGinley covered health and medicine for The Washington Post, focusing on the Food and Drug Administration as well as cancer research and treatment. She was previously The Post's health ...

Tuesday's big news with Apellis Pharmaceuticals (NASDAQ: APLS) wasn't all that favorable to the company. It released its third-quarter results, and the market wasn't all that pleased with the figures.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases ...